Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host (Q30395200)

10 October 2017

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host (English)

1 reference

10 October 2017

Hugues de Lavallade

1

1 reference

10 October 2017

Paula Garland

2

1 reference

10 October 2017

Takuya Sekine

3

1 reference

10 October 2017

Katja Hoschler

4

1 reference

10 October 2017

David Marin

5

1 reference

10 October 2017

Kate Stringaris

6

1 reference

10 October 2017

Eva Loucaides

7

1 reference

10 October 2017

Katherine Howe

8

1 reference

10 October 2017

Richard Szydlo

9

1 reference

10 October 2017

Ed Kanfer

10

1 reference

10 October 2017

Donald Macdonald

11

1 reference

10 October 2017

Peter Kelleher

12

1 reference

10 October 2017

Nichola Cooper

13

1 reference

10 October 2017

Ahmad Khoder

14

1 reference

10 October 2017

Ian H Gabriel

15

1 reference

10 October 2017

Dragana Milojkovic

16

1 reference

10 October 2017

Jiri Pavlu

17

1 reference

10 October 2017

John M Goldman

18

1 reference

10 October 2017

Jane F Apperley

19

1 reference

10 October 2017

Katayoun Rezvani

20

1 reference

10 October 2017

22 October 2010

1 reference

10 October 2017

1 reference

10 October 2017

96

1 reference

10 October 2017

2

1 reference

10 October 2017

307-314

1 reference

Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation

10 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Clinical and immunologic predictors of influenza illness among vaccinated older adults

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Utility of influenza vaccination for oncology patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Response to a monovalent 2009 influenza A (H1N1) vaccine.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Influenza vaccination in hematopoietic SCT recipients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Influenza vaccination and chemotherapy: a shot in the dark?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Response to influenza virus vaccine in children receiving chemotherapy for malignancy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Rituximab treatment results in impaired secondary humoral immune responsiveness.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

26 November 2018

1 reference

12 December 2020

Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy

1 reference

12 December 2020

Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study

1 reference

12 December 2020

T cell responses are better correlates of vaccine protection in the elderly

1 reference

12 December 2020

10.3324/HAEMATOL.2010.032664

Identifiers

DOI

1 reference

10 October 2017

1 reference

10 October 2017

PubMed publication ID

20971824

1 reference